Olaratumab + Liposomal Doxorubicin (n = 62) | Liposomal Doxorubicin(n = 61) | Hazard Ratioa | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
No. | Events | Median, monthsb | 95% CIb | No. | Events | Median, monthsb | 95% CIb | HR | 95% CI | |
Stratification factor (from IVRS) | ||||||||||
Platinum-refractory | 15 | 12 | 5.5 | (1.6–9.2) | 16 | 13 | 3.7 | (1.9–9.2) | 0.85 | (0.38–1.91) |
Platinum-resistant | 47 | 37 | 3.7 | (1.9–6.2) | 45 | 34 | 4.0 | (2.7–7.8) | 1.13 | (0.71–1.80) |